Advertisement

Advertisement

HALO Stock Latest News

Halozyme Therapeutics Adds James Daly to Board

Company AnnouncementsHalozyme Therapeutics Adds James Daly to Board

Halozyme Raises $1.5 Billion via Convertible Notes Offering

PremiumCompany Announcements

Halozyme Raises $1.5 Billion via Convertible Notes Offering

9d ago

Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

PremiumCompany Announcements

Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

14d ago

Closing Bell Movers: Generac up over 30% on Amazon pact

PremiumThe Fly

Closing Bell Movers: Generac up over 30% on Amazon pact

15d ago

Halozyme announces $1.05B convertible notes offering

PremiumCompany Announcements

Halozyme announces $1.05B convertible notes offering

15d ago

Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes

PremiumThe FlyHalozyme announces proposed offering of $1.05B of 2033 convertible senior notes

15d ago

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

The Fly

H.C. Wainwright views Novartis, Alteogen pact as negative for Halozyme

30d ago

Halozyme Appoints Dannielle Appelhans to Board of Directors

Company Announcements

Halozyme Appoints Dannielle Appelhans to Board of Directors

1M ago

Halozyme Earnings Call Highlights Surging Royalties, Raised Outlook

PremiumCompany Announcements

Halozyme Earnings Call Highlights Surging Royalties, Raised Outlook

2M ago

Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged

PremiumRatings

Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged

2M ago

Halozyme price target raised to $95 from $75 at Wells Fargo

PremiumThe Fly

Halozyme price target raised to $95 from $75 at Wells Fargo

2M ago

Halozyme price target raised to $105 from $93 at Morgan Stanley

PremiumThe Fly

Halozyme price target raised to $105 from $93 at Morgan Stanley

2M ago

Halozyme price target raised to $105 from $96 at TD Cowen

PremiumThe FlyHalozyme price target raised to $105 from $96 at TD Cowen

2M ago

Halozyme price target raised to $95 from $75 at Wells Fargo

The Fly

Halozyme price target raised to $95 from $75 at Wells Fargo

2M ago

Leerink upgraded Halozyme to Outperform on growth, market leadership

The Fly

Leerink upgraded Halozyme to Outperform on growth, market leadership

2M ago

Halozyme upgraded to Outperform from Market Perform at Leerink

PremiumThe Fly

Halozyme upgraded to Outperform from Market Perform at Leerink

2M ago

Halozyme price target raised to $93 from $92 at Citizens

PremiumThe Fly

Halozyme price target raised to $93 from $92 at Citizens

2M ago

Halozyme price target raised to $115 from $95 at H.C. Wainwright

PremiumThe Fly

Halozyme price target raised to $115 from $95 at H.C. Wainwright

2M ago

Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82

PremiumThe Fly

Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82

2M ago

Halozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25

PremiumThe FlyHalozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25

2M ago

Is HALO a Buy, Before Earnings?

Pre-Earnings

Is HALO a Buy, Before Earnings?

2M ago

Halozyme announces global collaboration, license agreement with Incyte

The Fly

Halozyme announces global collaboration, license agreement with Incyte

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >